3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
2
Endometrial Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Rectal Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Cystadenocarcinoma, Serous
1
Carcinoma in Situ
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Paclitaxel
328
Carboplatin
323
Bevacizumab
171
Gemcitabine
106
liposomal doxorubicin
104
pembrolizumab
101
Cyclophosphamide
96
Topotecan
94
olaparib
92
Cisplatin
92
niraparib
69
Docetaxel
57
Taxes
52
Doxorubicin
51
Drug Therapy
45
fludarabine
40
Filgrastim
39
Nivolumab
37
Magnetic Resonance Spectroscopy
34
Surveys and Questionnaires
33
Specimen Handling
33
Etoposide
32
Hyperthermic Intraperitoneal Chemotherapy
31
Blood Specimen Collection
29
Immunoglobulin G
27
Disulfides
27
Peripheral Blood Stem Cell Transplantation
26
Cytoreduction Surgical Procedures
25
Albumin-Bound Paclitaxel
25
durvalumab
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Diphenhydramine
×
Gynecologic
×
Clear all
NCT04237090
2020-10-12
PREMED-F1
Ciusss de L'Est de l'Île de Montréal
Phase 3
Completed
27 enrolled